Equities
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)6.99
  • Today's Change-0.05 / -0.71%
  • Shares traded1.95m
  • 1 Year change+6.88%
  • Beta1.1630
Data delayed at least 15 minutes, as of Nov 14 2024 03:59 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CNY
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments8,2259,0116,246
Total Receivables, Net383190124
Total Inventory119659.92
Prepaid expenses393438
Other current assets, total------
Total current assets8,7659,3006,417
Property, plant & equipment, net1,089952576
Goodwill, net3.133.133.13
Intangibles, net394134
Long term investments5.6612326
Note receivable - long term5.42----
Other long term assets7.204.823.24
Total assets9,91910,3217,398
LIABILITIES
Accounts payable13511985
Accrued expenses9110864
Notes payable/short-term debt000
Current portion long-term debt/capital leases1,2791,21720
Other current liabilities, total588631160
Total current liabilities2,0942,075329
Total long term debt70351,248
Total debt1,3491,2531,268
Deferred income tax----0
Minority interest334754
Other liabilities, total574566161
Total liabilities2,7712,7241,793
SHAREHOLDERS EQUITY
Common stock0.020.020.02
Additional paid-in capital11,86811,7569,372
Retained earnings (accumulated deficit)(4772)(4098)(3276)
Treasury stock - common------
Unrealized gain (loss)(6.04)(6.04)(6.04)
Other equity, total58(56)(485)
Total equity7,1487,5975,605
Total liabilities & shareholders' equity9,91910,3217,398
Total common shares outstanding1,7631,7641,500
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.